BACKGROUND: In HIV-infected patients, therapeutic drug monitoring (TDM) of antiretroviral drugs is recommended in special populations and in specific situations to optimize therapy. Currently, TDM is performed via measurement of drug plasma concentrations; however, dried blood spots (DBS) may offer a patient friendly and cost-effective alternative. Therefore, this proof-of-concept study assessed the feasibility of TDM of antiretroviral drugs using DBS with sampling at home. METHODS: Included patients were instructed to sample three DBS just before drug intake at three consecutive days at home and one DBS sample together with their routine venous sampling. All samples were analysed using liquid chromatography coupled to tandem mass spectrometry. Feasibility was investigated with a questionnaire and via determination of the calculated plasma trough concentrations. RESULTS: In total, 50 patients (48 male, mean age 50 years [range 29-69]) have been included, of whom most were virologically and immunologically well-controlled. In total, 200 DBS were collected, of which 87.5% were suitable for analysis. The questionnaire showed that most patients (68%) successfully obtained their first DBS and 51% preferred DBS over plasma sampling. Plasma trough concentrations could adequately be determined from DBS. CONCLUSIONS: This proof-of-concept study confirms the feasibility of TDM of antiretroviral drugs using DBS with sampling at home, thereby opening the possibility to obtain trough concentrations at home in populations where venous sampling is difficult.
BACKGROUND: In HIV-infectedpatients, therapeutic drug monitoring (TDM) of antiretroviral drugs is recommended in special populations and in specific situations to optimize therapy. Currently, TDM is performed via measurement of drug plasma concentrations; however, dried blood spots (DBS) may offer a patient friendly and cost-effective alternative. Therefore, this proof-of-concept study assessed the feasibility of TDM of antiretroviral drugs using DBS with sampling at home. METHODS: Included patients were instructed to sample three DBS just before drug intake at three consecutive days at home and one DBS sample together with their routine venous sampling. All samples were analysed using liquid chromatography coupled to tandem mass spectrometry. Feasibility was investigated with a questionnaire and via determination of the calculated plasma trough concentrations. RESULTS: In total, 50 patients (48 male, mean age 50 years [range 29-69]) have been included, of whom most were virologically and immunologically well-controlled. In total, 200 DBS were collected, of which 87.5% were suitable for analysis. The questionnaire showed that most patients (68%) successfully obtained their first DBS and 51% preferred DBS over plasma sampling. Plasma trough concentrations could adequately be determined from DBS. CONCLUSIONS: This proof-of-concept study confirms the feasibility of TDM of antiretroviral drugs using DBS with sampling at home, thereby opening the possibility to obtain trough concentrations at home in populations where venous sampling is difficult.
Authors: Dianna E B Hergott; Tonny J Owalla; Jennifer E Balkus; Bernadette Apio; Jimmy Lema; Barbara Cemeri; Andrew Akileng; Annette M Seilie; Chris Chavtur; Weston Staubus; Ming Chang; Thomas G Egwang; Sean C Murphy Journal: Malar J Date: 2022-07-14 Impact factor: 3.469
Authors: Kim C M van der Elst; Lambert F R Span; Kai van Hateren; Karin M Vermeulen; Tjip S van der Werf; Ben Greijdanus; Jos G W Kosterink; Donald R A Uges; Jan-Willem C Alffenaar Journal: Antimicrob Agents Chemother Date: 2013-07-29 Impact factor: 5.191
Authors: Christel C L M Boons; Lonneke Timmers; Jeroen J W M Janssen; Eleonora L Swart; Jacqueline G Hugtenburg; N Harry Hendrikse Journal: Eur J Clin Pharmacol Date: 2019-02-07 Impact factor: 2.953
Authors: Sanjiv M Baxi; Eric Vittinghoff; Peter Bacchetti; Yong Huang; Kata Chillag; Ryan Wiegand; Peter L Anderson; Robert Grant; Ruth M Greenblatt; Susan Buchbinder; Monica Gandhi; Albert Y Liu Journal: PLoS One Date: 2018-01-09 Impact factor: 3.240
Authors: A E C A B Willemsen; L M Knapen; Y M de Beer; R J M Brüggemann; S Croes; C M L van Herpen; N P van Erp Journal: Eur J Clin Pharmacol Date: 2017-12-08 Impact factor: 2.953
Authors: Herman Veenhof; Job Frank Martien van Boven; Anna van der Voort; Stefan Philip Berger; Stephanus Johannes Leonardus Bakker; Daniël Johannes Touw Journal: Br J Clin Pharmacol Date: 2020-02-28 Impact factor: 4.335
Authors: Hylke Waalewijn; Anna Turkova; Natella Rakhmanina; Tim R Cressey; Martina Penazzato; Angela Colbers; David M Burger Journal: Ther Drug Monit Date: 2019-08 Impact factor: 3.681
Authors: Tamara Prinsenberg; Sjoerd Rebers; Anders Boyd; Freke Zuure; Maria Prins; Marc van der Valk; Janke Schinkel Journal: PLoS One Date: 2020-04-14 Impact factor: 3.240